CoChat

Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira)

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: Insulin degludec/liraglutide (IDegLira) is a novel combination of insulin degludec (IDeg) and liraglutide. This trial investigated the contribution of the liraglutide component of IDegLira versus IDeg alone on efficacy and safety in patients with type 2 diabetes. RESEARCH DESIGN AND METHODS: In a 26-week, double-blind trial, patients with type 2 diabetes (A1C 7.5–10.0% [58–86 mmol/mol]) on basal insulin (20–40 units) and metformin with or without sulfonylurea/glinides were randomized (1:1) to once-daily IDegLira + metformin or IDeg + metformin with titration aiming for fasting plasma glucose between 4 and 5 mmol/L. Maximum allowed doses were 50 dose steps (equal to 50 units IDeg plus 1.8 mg liraglutide) and 50 units for IDeg. The primary end point was change in A1C from baseline. RESULTS: A total of 413 patients were randomized (mean A1C 8.8% [73 mmol/mol]; BMI 33.7 kg/m2). IDeg dose, alone or as part of IDegLira, was equivalent (45 units). A1C decreased by 1.9% (21 mmol/mol) with IDegLira and by 0.9% (10 mmol/mol) with IDeg (estimated treatment difference −1.1% [95% CI −1.3, −0.8], −12 mmol/mol [95% CI −14, −9; P < 0.0001). Mean weight reduction with IDegLira was 2.7 kg vs. no weight change with IDeg, P < 0.0001. Hypoglycemia incidence was comparable (24% for IDegLira vs. 25% for IDeg). Overall adverse events were similar, and incidence of nausea was low in both groups (IDegLira 6.5% vs. IDeg 3.5%). CONCLUSIONS: IDegLira achieved glycemic control superior to that of IDeg at equivalent insulin doses without higher risk of hypoglycemia and with the benefit of weight loss. These findings establish the efficacy and safety of IDegLira and the distinct contribution of the liraglutide component.

Overview

Integrity signals

Registry

Crossref · 10.2337/dc14-0785

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 27 references

Cited by

See all 265

Metadata

Authors
Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • University of Copenhagen (DK)
  • SSM Health Care (US)
  • Texas Diabetes & Endocrinology (US)
  • Novo Nordisk (Denmark) (DK)
  • Endocrine and Metabolic Consultants, Clinical Research, Rockville, MD
Corresponding author
Buse, John B.
Venue
Diabetes Care
Published
2014-10-10
Volume
37
Issue
11
Pages
2926-2933
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2126862523
Cited by
259
References
27
Citations by year
2026: 10 · 2025: 13 · 2024: 10 · 2023: 11 · 2022: 14 · 2021: 14 · 2020: 16 · 2019: 30 · 2018: 39 · 2017: 41 · 2016: 30 · 2015: 26 · 2014: 4
FWCI
26.94
Type
journal article
Language
en
Open access
closed
Locations
  • Diabetes Care (publishedVersion)
  • PubMed (publishedVersion)
Funders
Novo Nordisk Fonden (NNF12OC1015904)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
insulin degludec, liraglutide, IDegLira, type 2 diabetes, glycemic control, HbA1c, weight loss, hypoglycemia, basal insulin, metformin, GLP-1 receptor agonists, nausea, fixed-dose combination
MeSH terms
Liraglutide, Aged, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Combinations, Drug Therapy, Combination, Female, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Sulfonylurea Compounds, Weight Loss, Treatment Outcome, Insulin, Long-Acting, Glucagon-Like Peptide 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). https://app.cochat.ai/papers/10.2337/dc14-0785
The paper
Buse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014). Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira). Diabetes Care. https://doi.org/10.2337/dc14-0785

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.